ARQT
NASDAQ
US
Arcutis Biotherapeutics, Inc. - Common stock
$23.63
▼ $-0.47
(-1.95%)
Vol 1.1M
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$3.6B
ROE
-29.7%
Margin
-13.9%
D/E
68.64
Beta
1.70
52W
$11–$32
Wall Street Consensus
14 analysts · Apr 20264
Strong Buy
8
Buy
2
Hold
0
Sell
0
Strong Sell
85.7%
Buy Rating
Price Chart
Similar Stocks
DNLI
Denali Therapeutics Inc
$2.6B
DYN
Dyne Therapeutics Inc
$3.2B
TNGX
Tango Therapeutics Inc
$1.2B
TWST
Twist Bioscience Corp
$1.9B
CPRX
Catalyst Pharmaceuticals Inc
P/E 13.2
$2.9B
VERA
Vera Therapeutics, Inc
$3.5B
IDYA
IDEAYA Biosciences Inc
$3.0B
TVTX
Travere Therapeutics Inc
$3.4B
ORKA
Oruka Therapeutics Inc
$1.5B
About Arcutis Biotherapeutics, Inc. - Common stock
ARQT - біотехнологічна компанія, що спеціалізується на розробці та комерціалізації інноваційних методів лікування раку. Їхня унікальна платформа націлена на подолання резистентності до терапії, що дає їм конкурентну перевагу. Компанія займає нішу на ринку, пропонуючи персоналізовані рішення для онкологічних хворих.
Earnings
Beat rate: 100.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $0.12 | $0.13 | +$0.01 |
| Sep 2025 | $-0.10 | $0.06 | +$0.16 |
| Jun 2025 | $-0.16 | $-0.13 | +$0.03 |
| Mar 2025 | $-0.21 | $-0.20 | +$0.01 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $71.4M | $65.8M | $81.5M | $99.2M | $129.5M |
| Net Income | — | -$10.8M | -$25.1M | -$15.9M | $7.4M | $17.4M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -62.6% | -62.6% | -62.6% | -29.7% | -29.7% | -29.7% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -19.5% | -35.4% | -35.4% | -13.9% | -13.9% | -13.9% |
| Gross Margin | 90.8% | 89.1% | 89.1% | 90.0% | 90.0% | 90.0% |
| D/E Ratio | 77.75 | 77.75 | 77.75 | 68.64 | 68.64 | 68.64 |
| Current Ratio | 3.20 | 3.20 | 3.20 | 3.50 | 3.50 | 3.50 |
Key Ratios
ROA (TTM)
-12.5%
P/S (TTM)
11.19
P/B
10.3
EPS (TTM)
$-0.35
CF/Share
$-4.34
52W High
$31.77
52W Low
$11.13
$11.13
52-Week Range
$31.77
Financial Health
Free Cash Flow
$26.2M
Net Debt
$71.3M
Cash
$42.9M
Total Debt
$114.2M
As of Dec 31, 2025
How does ARQT compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
ARQT valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
11.2
▼
13%
below
peers
(12.9)
vs Peers
vs Industry
Fair value
P/B ratio
10.4
▲
321%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
ARQT profitability vs Biotechnology peers
ROE
-29.7%
▲
56%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
-13.9%
▲
95%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
90.0%
▲
14%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-12.5%
▲
73%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
ARQT financial health vs Biotechnology peers
D/E ratio
68.6
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
3.5
▼
21%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
1.7
▲
75%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
ARQT fundamentals radar
ARQT
Peer median
Industry
ARQT profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ARQT vs peers: key metrics
Latest News
No related news yet